Latest Biotech News

Tempus AI agreed to acquire Personalis for about $1.5 billion, adding tumor-informed minimal residual disease (MRD) testing to its diagnostics platform. The deal values Personalis at $16.25 per...

Mission Therapeutics divested its kidney asset MTX652 to Dimerix in a deal worth up to $292 million, redirecting resources toward its USP30 inhibitor Parkinson’s program. Mission will receive $5...

Samsung Biologics agreed to acquire Swiss CDMO PolyPeptide for about $1.8 billion in cash, signaling a push deeper into peptide ingredient manufacturing. The transaction would extend Samsung...

A multicenter genomics study published in Science Advances identified genetic variants in the molecular target of praziquantel—TRPM pzQ—associated with reduced drug sensitivity in Schistosoma...

Tempus’ acquisition plan for Personalis doubles down on diagnostic data and automation in MRD testing, building directly on the existing NeXT Personal commercialization partnership. In a...

Bristol Myers Squibb said it will build a supercomputer system with Nvidia intended to become the “most powerful” AI infrastructure in life sciences, deepening the companies’ R&D partnership. The...

A new report from the Peterson Health Technology Institute argues that current healthcare payment models are misaligned with clinical AI deployment and could increase costs if left unchanged. The...

The FDA’s policy of publishing complete response letters (CRLs) for rejections has encountered legal uncertainty, according to experts and session discussions tied to the BIO International...

Immix Biopharma shares fell 14% after investors learned that its chief medical officer, Richard Graydon (alias), had been a fugitive from Rhode Island on sexual assault charges. The report states...

Legend Biotech fell about 10% despite record second-quarter Carvykti sales after comments in a J&J earnings call drew investor attention. Johnson & Johnson reported Carvykti revenue of $657...

Tempus AI agreed to buy Personalis in a deal valued at about $1.5 billion, extending Tempus’ reach in minimal residual disease testing. Personalis shareholders will receive $16.25 per share in the...

Bristol Myers Squibb expanded its relationship with Nvidia, saying it will build a “most powerful” AI supercomputer factory in biopharma using Nvidia DGX SuperPOD infrastructure and AIDGX Vera...

The FDA’s push for greater transparency around complete response letters (CRLs) is facing mounting legal uncertainty, with experts warning the initiative may conflict with rules on the...

Rare disease drugmakers are lobbying the Trump administration to exclude their treatments from Medicare pilots aimed at cutting brand-drug prices. The Rare Disease Company Coalition met with the...

Researchers published a pan-cancer patient-derived organoid (PDO) platform spanning 220 organoids from 191 patients across 15 cancer types, reporting high fidelity to parent tumors and...

Mission Therapeutics divested its kidney drug asset MTX652 to Dimerix in a deal worth up to $292 million, aiming to sharpen each company’s development focus. Dimerix will pay $5 million upfront,...

Axiom Biosciences reported early-phase positive results for a mesenchymal stem cell therapy in newborns with severe brain injury, with plans to expand development into ischemic stroke. The news...

Latigo Biotherapeutics filed for an IPO as it prepares to advance non-opioid pain candidates targeting the Nav1.8 channel. The company’s oral small-molecule Nav1.8 inhibitor LTG-001 completed a...

Scribe Therapeutics filed IPO paperwork to fund a clinical push for lipid-lowering genetic medicines, with proceeds earmarked for its lead PCSK9-targeting gene-silencing program STX-1150 and...

Investigators identified blood plasma protein patterns linked to Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, reporting a 21-protein panel. The work is described as...